Development of an inactivated candidate vaccine against Chandipura virus (Rhabdoviridae: Vesiculovirus)

Vaccine

Volumn 29, Issue 28, 2011, Pages 4613-4617

  Jadi, R S ^a   Sudeep, A B ^a   Barde, P V ^a   Arankalle, V A ^a   Mishra, A C ^a  

^a NATIONAL INSTITUTE OF VIROLOGY   (India)

Author keywords

Candidate vaccine; Chandipura virus; Virus encephalitis

Indexed keywords

ALUMINUM PHOSPHATE; CHANDIPURA VIRUS VACCINE; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; SUCROSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CHANDIPURA VIRUS; CONTROLLED STUDY; DOSE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SEROCONVERSION; ULTRACENTRIFUGATION; VESICULAR STOMATITIS VIRUS; VIRUS INACTIVATION; VIRUS PURIFICATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; IMMUNIZATION; MICE; RHABDOVIRIDAE INFECTIONS; TREATMENT OUTCOME; VACCINES, INACTIVATED; VERO CELLS; VESICULOVIRUS; VIRAL VACCINES;

EID: 79958088803     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.063     Document Type: Article

References (19)

1. Rao B.L., Basu A., Wairagkar N.S., Gore M.M., Arankalle V.A., Thakare J.P., et al. A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh, India, in 2003, associated with Chandipura virus. Lancet 2004, 364:869-874.
2. Chadha M.S., Arankalle V.A., Jadi R.S., Joshi M.V., Thakare J.P., Mahadev P.V., et al. An outbreak of Chandipura virus encephalitis in the eastern districts of Gujarat state, India. Am J Trop Med Hyg 2005, 73:566-570.
3. Tandale B.V., Tikute S.S., Arankalle V.A., Sathe P.S., Joshi M.V., Ranadive S.N., et al. Chandipura virus: a major cause of acute encephalitis in children in North Telangana, Andhra Pradesh, India. J Med Virol 2008, 80:118-124.
4. Gurav Y.K., Tandale B.V., Jadi R.S., Gunjikar R.S., Tikute S.K., Jamgaonkar A.V., et al. Chandipura virus encephalitis outbreak among children in Nagpur division, Maharashtra, 2007. Indian J Med Res 2010, 132:395-399.
5. Jadi R.S., Sudeep A.B., Kumar S., Arankalle V.A., Mishra A.C. Chandipura virus growth kinetics in certain cell lines and embryonated eggs: a comparative study. Indian J Med Res 2010, 132:155-159.
6. Lowery O.H., Rosebrough N.J., Farr Al, Randall R.J. Protein measurement with folin phenol reagent. J Biol Chem 1951, 193:265-275.
7. Venkateswarlu C.H., Arankalle V.A. Recombinant glycoprotein based vaccine for Chandipura virus infection. Vaccine 2009, 27:2845-2850.
8. Venkateswarlu C.H., Arankalle V.A. Evaluation of the immunogenicity of a recombinant glycoprotein-based Chandipura vaccine in combination with commercially available DPT vaccine. Vaccine 2010, 28:1463-1467.
9. Budowsky E.I., Bresler S.E., Friedman E.A., Zheleznova N.V., Noskov F.S. Principles of selective inactivation of viral genome. VI. Inactivation of the Infectivity of the Influenza virus by the action of beta-propiolactone. Vaccine 1991, 9:398-402.
10. Appaiahgari M.B., Vrati S. Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells. Vaccine 2004, 22:3669-3675.
11. Tiwari M., Parida M., Santhosh S.R., Khan M., Dash P.K., Rao P.V. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 2009, 27:2513-2522.
12. Shu de J., Pye D., Cox J.C. Inactivation of poliovirus with β-propiolactone. J Virol 1986, 14:103-109.
13. Lawrence S.A. Beta-propiolactone: viral inactivation in vaccines and plasma products. J Pharm Sci Technol 2000, 54:209-217.
14. Capodici J., Maigetter R., Revai M., Latzo J., Watson F., Sung J., et al. Large-scale beta-propiolactone inactivation of HIV for vaccines. Bioprocess Technol 2006, 36-41.
15. Perrin P., Morgeaux S. Inactivation of DNA by β-propiolactone. Biologicals 1995, 23:207-211.
16. Vogel F.R. Adjuvants in perspective. Dev Biol Stand 1998, 92:241-248.
17. Chang S., Warner J., Liang L., Fairman J. A novel vaccine adjuvant for recombinant flu antigens. Biologicals 2009, 37:141-147.
18. Ninomiya A., Imai M., Tashiro M., Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007, 25:3554-3560.
19. Hansen B., Belfast M., Soung G., Song L., Egan P.M., Capen R., et al. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine 2009, 27:888-892.